4basebio plc (4BB), the UK-listed biotech company, has received a major shareholding notification disclosing that Wilhelm K. T. Zours of Heidelberg, Germany, holds 31.733950% of the company's voting rights, following a threshold crossing on 10 November 2026. The notification, submitted to 4basebio on 12 November 2026, was filed under the TR-1 standard form for major holdings as required by the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The disclosure indicates a slight reduction from Zours's previously notified position of 32.033704%, a movement that investors in the AIM-traded company may note given the scale of his overall stake.
Key Points
- 4basebio plc (4BB), ISIN GB00BMCLYF79, UK-listed biotech company
- Wilhelm K. T. Zours has disclosed a total voting rights position of 31.733950%, equating to 6,103,939 voting rights held indirectly
- The threshold was crossed on 10 November 2026; the issuer was notified on 12 November 2026; previous notified position was 32.033704%
- Investors should watch for any further TR-1 filings that could indicate continued movement in Zours's position across his chain of controlled entities
Wilhelm Zours's 31.73% Indirect Stake in 4basebio Held Through Five Controlled Entities
All 6,103,939 voting rights are held indirectly by Zours, with zero direct voting rights recorded in the notification. The stake is distributed across five named controlled undertakings: DELPHI Unternehmensberatung Aktiengesellschaft holds 3.319184%, SPARTA Invest AG holds 7.027487%, 2invest AG holds 16.636347%, and Latonba AG holds 4.190675%. VV Beteiligungen Aktiengesellschaft and Deutsche Balaton Aktiengesellschaft are also listed in the chain of controlled undertakings, though specific percentage breakdowns at or above the notifiable threshold were not provided for those entities in the announcement.
Reduction from 32.03% Previous Notification Triggers Fresh DTR Disclosure Obligation for 4basebio
The filing was triggered by either an acquisition or disposal of voting rights, or an event changing the breakdown of voting rights, as stated in the notification. The movement from 32.033704% to 31.733950% represents a decrease of approximately 0.3 percentage points, though the precise mechanism — whether a disposal of shares or a dilutive corporate event affecting the voting rights breakdown — is not specified in the announcement. The notification was completed in Heidelberg, Germany, consistent with the registrant's location, and carries no additional commentary from either 4basebio or Zours beyond the mandated disclosure fields.
Concentration Risk Highlighted as Single Investor Controls Nearly a Third of 4basebio Voting Rights
The scale of Zours's position, at nearly one third of total voting rights in 4basebio, represents a significant concentration of influence within a single investor and his associated entities. Such concentrated indirect ownership structures, operating through multiple investment vehicles, are common among German strategic investors active in specialist European biotechnology and life sciences companies. For 4basebio shareholders, the ongoing presence of a dominant indirect holder introduces governance considerations that are worth monitoring alongside any future operational or financing announcements from the company.




Please wait processing your request...